Pharma: Acquisitions to intensify? - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma: Acquisitions to intensify?

Feb 13, 2007

India Inc. has been witnessing increased activity on the M&A front across sectors of late. First it was Tata Steel's acquisition of Corus, then Vodafone's acquisition of 67% stake in Hutchison Essar and finally, Hindalco's bid to acquire Novelis for US$ 6 bn. These acquisitions highlight the fact that the deal size is getting bigger and bigger. Similarly, acquisitions have been gathering pace in the Indian pharma industry as well. Two big acquisitions by the behemoths, Dr.Reddy's (Betapharm) and Ranbaxy (Terapia) prove testimonial to the fact. In fact, with the European company Merck KgaA looking to put up its generics business Merck Generics on the block, the scramble amongst both global generic companies and Indian generic companies to acquire scale seems to have intensified. Here, we look at some of the pros and challenges that Indian pharma companies are expected to face on the consolidation front going forward. The pros...
Scale: It is a well documented fact that the US generics market has been facing intense price erosion, which has been due to increasing competition from both Indian and global generic players. It must be noted that the pharma distribution chain in the US market is highly consolidated with around 3 companies dominating around 70% of the distribution network for pharma products. This means that having the required scale is important in increasing the distribution reach and attaining significant market share in a particular product in this highly competitive market. Acquiring scale holds true in other markets as well in cornering a larger chunk of the market. It must be noted that the gap between Teva and Sandoz (the top two players at present) and the rest of the pack has widened and thus there is ample scope to reduce the same, thereby intensifying the need for consolidation.

Access to new geographies: Given the fact that the US market is highly competitive, Indian companies are increasingly looking to establish a presence in other geographies to de-risk the revenue profile. However, as per our interaction with a leading pharma company, it is not easy to set up operations in any country right from scratch and hence an acquisition provides a ready platform to strengthen presence in a particular market. Given the fact that different countries have a different regulatory environment and different market conditions, acquiring a company in a particular market enables the acquiring company to strengthen its foothold in the market at a faster pace. For instance, Dr.Reddy's had a marginal presence in Germany initially and the acquisition of Betapharm has provided the former a vehicle to strengthen its reach in the German market, which is the largest generics market in Europe.

Strengthening product portfolio: The rising competition in the generics space has led to a commoditisation of plain vanilla generics and thus there has been increased focus on niche and technology intensive products where the level of competition is relatively lesser. For instance, in FY05, as a part of its strategy to cater to the specialty segment, Dr. Reddy's acquired Trigenesis, a US based dermatology products company for a consideration of US$ 11 m in order to establish a footprint in the fast growing and niche dermatology market.

The challenges...
Market and regulatory risks: This is one of the major challenges that Indian pharma companies have to contend with while acquiring a company, as it is difficult to take a call on the likely regulatory changes that may take place in any country. To put things into perspective, a host of healthcare reforms in Germany and France have taken its toll on the fortunes of Indian companies having operations in these regions. For instance, in the lucrative German market, the government has made some regulatory changes, which has prompted the top companies including Betapharm to undertake price cuts on their products to comply with these changes. This has put pressure on the margins of Betapharm and could consequently increase the payback period for Dr.Reddy's. Similarly, regulatory changes in Brazil has resulted in Ranbaxy having to re-file applications for its generic products impacting sales from this region in CY06.

Expensive valuations: In the scramble to acquire scale, the number of companies looking to acquire potential targets has gone up, but the number of companies up for sale have not been that many leading to a rise in valuations. In all the large acquisitions made in the global generics space in the last couple of years, the price to sales multiple has not been less than 2 times, which is a tad expensive. Besides this, many Indian companies have raised resources through the FCCB route for funding potential acquisitions. This means that in the event that the rupee depreciates, the value of the FCCBs will increase, leading to a rise in interest obligations, thereby affecting profitability. In the case of zero-coupon FCCBs (which have also gained popularity), while companies do not have to pay interest, payment pressures (magnified further by the rupee depreciation) could arise during the time of redemption.

To sum up...
Domestic pharma majors such as Ranbaxy and Cipla have evinced an interest in bidding for Merck Generics, which is currently the fifth largest player in the global generics market. With the latter having reported revenues of around US$ 2.5 bn in CY05, the deal size is not likely to be less than US$ 5 bn, which is not a small amount by any yardstick. Thus, while a large ticket acquisition will provide Indian generic companies the much needed scale to survive the tough conditions in the generics market and contribute to the overall performance in the long term, integration issues and funding for the same could put a strain on profitability in the medium term.


Equitymaster requests your view! Post a comment on "Pharma: Acquisitions to intensify?". Click here!

  

More Views on News

Your Queries on the 8-Year Cycle Answered (Fast Profits Daily)

Sep 25, 2020

You've sent in your queries on my videos on the 8-year greed and fear cycle in the market. I'll answer them in this video.

It's When You Sell that Counts (Profit Hunter)

Sep 25, 2020

How I alerted readers to the impending crash last week.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

How to Save Money by Exiting Stocks Before They Fall podcast (Views On News)

Sep 24, 2020

A penny saved is a penny earned. It doesn't matter where you enter. All that matter is where you exit. Watch this video to identify an opportune time to exit your investments and book profits.

ICICI Prudential ESG Fund: Aims for Sustainability (Outside View)

Sep 24, 2020

PersonalFN briefly explains the newly launched fund : ICICI Prudential ESG Fund.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

Sep 17, 2020

In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE SENSEX


Sep 25, 2020 (Close)

MARKET STATS